Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance.

Samsung arbitration decision and new HP license agreement drive Q2 results, exceeding outlookAnnualized recurring revenue1, at all-time high of $553 million, up 44% YoYCompany raises full year 2025 ...